Category: Spotlight

Avalon Health Economics will be at ISPOR New Orleans, May 18 through May 22, 2019
March 14, 2019 - 5:03 pm, by
Avalon Health Economics will be at ISPOR New Orleans, May 18 through May 22. We will be engaged in our usual array of posters, podium presentations, and short courses. If you are planning on attending, please let us know if you want to meet with any of our team!
Avalon Health Economics Collaborates with Acaster-LLoyd Consulting, Ltd.
December 26, 2018 - 12:36 pm, by
Avalon Health Economics is happy to announce an exciting new collaboration with the London-based Acaster-Lloyd Consulting, Ltd. Acaster-Lloyd, led by Sarah Acaster and Andrew Lloyd, is a leader in the area of clinical outcomes assessment (COA), including patient-reported outcomes, health-state utilities, strategy & analysis, preference surveys, instrument development, and qualitative research. The collaboration helps AHE...
Avalon Health Economics will be at ISPOR Barcelona, Nov. 10 through Nov. 14
September 28, 2018 - 11:31 am, by
Avalon Health Economics will be at ISPOR Barcelona, Nov. 10 through Nov. 14.  We will be engaged in our usual array of posters, podium presentations, and short courses.  If you are planning on attending, please let us know if you want to meet with any of our team!
Avalon CEO John Schneider will be speaking at the 4th Annual Conference on Health Outcomes, Data Communications, Market Access and Value-Based Contracting in Philadelphia, January 22-24, 2018.
December 1, 2017 - 4:02 pm, by
Avalon CEO John Schneider will be speaking at the 4th Annual Conference on Health Outcomes, Data Communications, Market Access and Value-Based Contracting in Philadelphia, January 22-24, 2018.
Avalon CEO John Schneider will be presenting on the panel of “Blockchain Use-Cases, Brainstorm: Replacing the Middleman: Healthcare, Retail, Finance and More” at the Blockchain Economic Forum 2017 in NYC on October 31st.
October 1, 2017 - 4:03 pm, by
Avalon CEO John Schneider will be presenting on the panel of “Blockchain Use-Cases, Brainstorm: Replacing the Middleman: Healthcare, Retail, Finance and More” at the Blockchain Economic Forum 2017 in NYC on October 31st.
Avalon Health Economics at the 20th Annual European Conference of ISPOR
October 1, 2017 - 3:59 pm, by
In our work in health economics and outcomes research (HEOR) for the life sciences, including biotechnology, pharmaceuticals, and medical devices, we must maintain close ties with our colleagues and stay up to date with the latest thinking on methods of technology assessment, trends in coverage decisions, and relevant changes in the policy and economic environment...
AHE Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access, Tuesday May 9th in Morristown, NJ
April 1, 2017 - 4:19 pm, by
Avalon Health Economics Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access Tuesday, May 9th at the Hyatt Regency in Morristown, NJ The past year has been a tumultuous time for US health economics, characterized by the confluence of at least six...
The Value of Biopharmaceutical Innovation in the U.S.
February 22, 2017 - 3:55 pm, by
There have been some negative reports recently regarding the pricing practices of some pharmaceutical companies. However, it is important to give at least equal consideration to the value derived from the intensive level of research and development undertaken by the biopharmaceutical industry in the U.S. The invention of new products and processes has been shown...
The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research
December 7, 2016 - 3:37 pm, by
Although there are a large number of public and private payers in the U.S., medical device and pharmaceutical manufacturers generally focus on two types of payers: (1) Medicare, which is administered by the Centers for Medicare and Medicaid Services (CMS) and covers individuals ages ≥ 65; and (2) private commercial payers (e.g., Blue Cross and...